|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our studies indicate a regulatory interaction between MYC and NMYC in neuroblastoma cells.
|
2810395 |
1989 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The N-myc gene, first detected by its homology to the second exon of the c-myc gene, is amplified and/or expressed in tumours or cell lines derived from neuroblastoma, retinoblastoma and SCLC.
|
2997622 |
1985 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both <i>in vitro</i> and <i>in vivo</i> Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma.<b>Conclusions:</b> The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma.
|
28270499 |
2017 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This hypothesis-driven systems bioinformatics work offered novel insights into the PRC2-mediated tumor cell growth and differentiation in neuroblastoma, which may exert oncogenic effects together with MYC regulation.
|
28984200 |
2017 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In sharp contrast to MYCN, enforced expression of c-MYC did not enhance OCT4 expression in human neuroblastoma cells.
|
25880909 |
2015 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We further demonstrated that BMI1 is a direct target gene of MYCN/MYC in 3 neuroblastoma cell lines: BE (2)-C, LAN1, and SH-SY5Y.
|
21856782 |
2011 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amplification or overexpression of neuronal MYC (MYCN) is associated with poor prognosis of human neuroblastoma.
|
26156430 |
2015 |
|
Neuroblastoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Amplification of the MYCN oncogene, a member of the MYC family of transcriptional regulators, is one of the most powerful prognostic markers identified for poor outcome in neuroblastoma, the most common extracranial solid cancer in childhood.
|
27448979 |
2016 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results, together with those obtained in human neuroblastoma, suggest that the distal part of the short arm of chromosome 1 harbors an unidentified tumor suppressor gene(s), whose inactivation may be involved in MYC family gene amplification (an example of genetic instability) in tumors of various cellular origins.
|
7913873 |
1994 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of the proto-oncogene, c-myc, in human neuroblastoma cells by reversible inhibition of cell growth.
|
1776829 |
1992 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To determine whether other modes of myc gene activation underlie progression of some neuroblastomas, 45 were analyzed for amplification of N-myc, c-myc and L-myc and 26 were studied for transcription of these oncogenes.
|
2302711 |
1990 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MYC coordinately regulates polyamine homeostasis as these essential cations support MYC functions, and drugs that antagonize polyamine sufficiency have synthetic-lethal interactions with MYC Neuroblastoma is a lethal tumor in which the MYC homologue MYCN, and ODC1, the rate-limiting enzyme in polyamine synthesis, are frequently deregulated so we tested optimized polyamine depletion regimens for activity against neuroblastoma.
|
27012811 |
2016 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Significant promoter activity in the presence of abundant Myc protein in amplified neuroblastoma lines indicates that autoregulation is disabled in this subset of tumors.
|
9365240 |
1997 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
High-risk neuroblastomas (an often lethal embryonal tumor in which MYC activation is paramount) deregulate numerous polyamine enzymes to promote the expansion of intracellular polyamine pools.
|
19789308 |
2009 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Applying this technique, we followed the metaphase location and interphase position of amplified DNA sequences corresponding to the SAMK, MYC, and MYCN genes in four cell lines derived from human tumors: two gastric carcinoma lines (KATO III and SNU-16), a neuroblastoma (NUB-7), and a neuroepithelioma (NUB-20) line.
|
1377938 |
1992 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These data highlight a novel route for cell death induction by PARP inhibitors and support their introduction, together with CHK1 inhibitors, in therapeutic approaches for neuroblastomas with high MYC(N) activity.
|
28394338 |
2017 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together our data suggest that these small molecules may hold potential as effective therapeutic agents for the treatment of neuroblastoma and other MYC-driven cancers.
|
24282277 |
2014 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of c-myc and N-myc genes by dsRNAs in carcinoma and neuroblastoma cells was investigated. siRNA-Ex3 targeted to the third exon of c-myc gene was found to decrease the level of c-myc but not N-myc mRNA and decrease the rate or even arrest proliferation of c-myc overexpressing cell lines KB-3-1 and SK-N-MC.
|
17341633 |
2006 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
N6,2'-O-dibutyryladenosine 3':5'cyclic monophosphate (Bt2cAMP) inhibited neuroblastoma cell growth by inhibiting c-MYC and HDAC8 expression and activating caspase 3.
|
30237861 |
2018 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Exposures mimicking conditions of CO (2) pneumoperitoneum lead to significant overexpression of C-MYC and HMGB-1 in neuroblastoma cells with decreased apoptosis.
|
19387923 |
2009 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We found that MELK is a direct transcription target of MYCN and MYC in NB, and MYCN increases MELK expression via direct promoter binding.
|
29416794 |
2018 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
As these results are of potential clinical importance, but not in agreement with our own initial observations, the putative correlation between ID2 and MYC(N) expression in neuroblastoma cell lines and tumors was reinvestigated.
|
12545167 |
2003 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
|
27197232 |
2016 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that MYCN/MYC-mediated overactivation of the metaphase-anaphase checkpoint synergizes with loss of p53-p21 function to prevent arrest or apoptosis of tetraploid neuroblastoma cells.
|
23186832 |
2013 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MYCN and MYC play a crucial role in determining the malignancy of unfavorable neuroblastomas, whereas high-level expression of the favorable neuroblastoma genes is associated with a good disease outcome and confers growth suppression of neuroblastoma cells.
|
24173829 |
2014 |